European Union Drugs Agency. (2026) Opioid agonist treatment – the current situation in Europe (European drug report 2026). Lisbon: EUDA.
External website: https://www.euda.europa.eu/publications/european-d...
People who use opioids represent nearly one third of the clients in specialist drug treatment. Opioid agonist treatment is the main form of treatment for opioid-related problems in these cases. On this page, you can find the latest analysis of the provision of opioid agonist treatment in Europe, including key data on coverage, the number of people in treatment, pathways to treatment and more.
This page is part of the European Drug Report 2026, the EUDA’s annual overview of the drug situation in Europe.
B Substances > Opioids (opiates) > Opioid product > Buprenorphine / Suboxone
B Substances > Opioids (opiates) > Opioid product > Methadone
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution) > Opioid agonist treatment (methadone maintenance / buprenorphine)
HJ Treatment or recovery method > Treatment outcome
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment factors
VA Geographic area > Europe
VA Geographic area > Europe > Ireland
Repository Staff Only: item control page